Reflector is Pharm Exec Europe's man inside the EU.
European efforts to crack down on safety and pricing issues in the marketing of medical devices may portend long-term problems for Big Pharma.
By the start of 2014, industry expects to have a clearer idea of how far the US-EU free trade pact is going.
The ?70 billion budget is still subject to final agreement on the European Union's overall spending plans for 2014-2020.
The European Union's attempt to update its transparency rules sparks new debate.
European Commision blocks the authorization of a life-saving liver drug outside of France.
For the second time in recent memory, a top European regulator leaves office abruptly and under a cloud of suspicion.
Europe's fiscal crisis is becoming a new rallying cry for patient groups—but regional unity is still elusive.
A recent medical device controversy in France has pushed European health ministers to agree on a crisis management program for the troubled sector.
Manufacturers, wholesalers, pharmacists and even parallel importers are uniting under a common blanket, writes Reflector.
Supply Chain Strategy: Managing risk and opportunity in a changing global landscape
Sponsored By PricewaterhouseCoopers LLP Optimizing the Multi-Sponsor REMS Experience (Risk Evaluation & Mitigation Strategies)
Sponsored By PricewaterhouseCoopers LLP Effective Resource Planning: Reducing Clinical Project Risk and Operating Cost
Sponsored By ClearTrial